CA2072891C - Proteines de fusion d'exotoxine de pseudomonas, avec modifications carboxyliques pour une cytotoxicite plus grande - Google Patents

Proteines de fusion d'exotoxine de pseudomonas, avec modifications carboxyliques pour une cytotoxicite plus grande

Info

Publication number
CA2072891C
CA2072891C CA002072891A CA2072891A CA2072891C CA 2072891 C CA2072891 C CA 2072891C CA 002072891 A CA002072891 A CA 002072891A CA 2072891 A CA2072891 A CA 2072891A CA 2072891 C CA2072891 C CA 2072891C
Authority
CA
Canada
Prior art keywords
molecule
amino acid
carboxyl
recognition
carboxyl terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002072891A
Other languages
English (en)
Other versions
CA2072891A1 (fr
Inventor
Ira Pastan
Vijay Chaudhary
David J. Fitzgerald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of CA2072891A1 publication Critical patent/CA2072891A1/fr
Application granted granted Critical
Publication of CA2072891C publication Critical patent/CA2072891C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Exotoxine de Pseudomonas, cytotoxique, recombinée spécifique à une cible. Lesdites toxines sont obtenues par insertion de molécules de reconnaissance spécifiques sur des sites de clonage spécifiques, dans au moins le domaine III au niveau de la terminaison carboxyle de la molécule PE. Diverses modifications de la terminaison carboxyle de la molécule PE augmentant la cytotoxicité, sont présentées.
CA002072891A 1990-01-02 1990-12-27 Proteines de fusion d'exotoxine de pseudomonas, avec modifications carboxyliques pour une cytotoxicite plus grande Expired - Fee Related CA2072891C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45963590A 1990-01-02 1990-01-02
US459,635 1990-01-02
PCT/US1990/007421 WO1991009949A1 (fr) 1990-01-02 1990-12-27 Exotoxine de pseudomonase, cytotoxique, recombinee specifique a une cible

Publications (2)

Publication Number Publication Date
CA2072891A1 CA2072891A1 (fr) 1991-07-03
CA2072891C true CA2072891C (fr) 1999-12-21

Family

ID=23825594

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002072891A Expired - Fee Related CA2072891C (fr) 1990-01-02 1990-12-27 Proteines de fusion d'exotoxine de pseudomonas, avec modifications carboxyliques pour une cytotoxicite plus grande

Country Status (5)

Country Link
EP (1) EP0509056A4 (fr)
JP (1) JP2610740B2 (fr)
AU (1) AU644139B2 (fr)
CA (1) CA2072891C (fr)
WO (1) WO1991009949A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631200B2 (en) * 1989-02-17 1992-11-19 Merck & Co., Inc. Production of modified pe40
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
NZ237758A (en) * 1990-04-17 1992-12-23 Shell Int Research (phenylalkyl) triphenylphosphonium salt derivatives and fungicidal compositions
JP2665827B2 (ja) * 1990-05-11 1997-10-22 アメリカ合衆国 低―動物毒性と高殺細胞活性の改良シュードモナス外毒素
PT2829283T (pt) 2003-04-30 2017-09-08 Univ Zuerich Método para tratamento do cancro utilizando uma imunotoxina
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
WO2016146833A1 (fr) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarqueurs de résistance à la nad(+)-diphtamide adp-ribosyltransférase
EP3184547A1 (fr) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anticorps anti-tpbg et procédés d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity

Also Published As

Publication number Publication date
JPH05502032A (ja) 1993-04-15
EP0509056A4 (en) 1993-02-17
AU644139B2 (en) 1993-12-02
CA2072891A1 (fr) 1991-07-03
EP0509056A1 (fr) 1992-10-21
WO1991009949A1 (fr) 1991-07-11
AU7242491A (en) 1991-07-24
JP2610740B2 (ja) 1997-05-14

Similar Documents

Publication Publication Date Title
US5705163A (en) Target-specific, cytotoxic, recombinant pseudomonas exotoxin
Chaudhary et al. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity.
US5328984A (en) Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
US5563046A (en) Fusion polypeptides and proteins
CN101432296B (zh) 聚乙二醇化的突变的肉毒梭菌毒素
US5914254A (en) Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US5082927A (en) Selectively cytotoxic IL-4-PE40 fusion protein
US6270993B1 (en) VEGF-binding polypeptide
US5700678A (en) Protein disulfide-isomerase and production thereof
CA2298015C (fr) Production d'erythropoietine par activation genique endogene
US7887801B2 (en) Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
CA2296841C (fr) Derives de tropoelastine
Prior et al. Translocation mediated by domain II of Pseudomonas exotoxin A: transport of barnase into the cytosol
JPH08506586A (ja) 殺菌性／浸透性が向上した安定なタンパク質生成物およびそれを含む薬剤組成物
CA1339894C (fr) Proteines hybrides a ballast eukaryotique
RU2144957C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPINS07, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ПРОИНСУЛИН ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО ПОЛИПЕПТИДА, СОДЕРЖАЩЕГО ПРОИНСУЛИН ЧЕЛОВЕКА
AU644139B2 (en) Target-specific, cytotoxic, recombinant pseudomonas exotoxin
CN100436581C (zh) 人干扰素α的表达和分泌载体及通过使用这种载体产生人干扰素α的方法
Canals et al. Production of engineered human pancreatic ribonucleases, solving expression and purification problems, and enhancing thermostability
JP2012511309A (ja) Ｅｃ−ｓｏｄのカルボキシル末端のアポプチンタンパク質導入ドメインの融合蛋白質
CA2240392C (fr) Formes multimeres de il-16, leur procede de fabrication et leur utilisation
CN113354738B (zh) 融合毒素VEGF165b/mGEL及其编码基因与应用
JPH0638787A (ja) 可溶性エリスロポエチン受容体蛋白質、およびそのアミノ酸配列をコードする遺伝子
JP2824503B2 (ja) エリスロポエチン活性増強物質およびその製造法
JP2006230251A (ja) 融合タンパク質発現ベクター

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed